Recently, we and others have described single cases or small studies of tumours with concomitant alterations of H3-K27M and mitogen-activated protein kinase (MAPK) pathway showing a possible longer survival compared to patients with DMG H3 K27-altered, BRAF and FGFR1 wild-type. This evidence concerns the gene FGFR1 and neoplasm.